Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer

Background: Ovarian cancer (OC) represents the seventh most lethal female tumors worldwide. The combination of PARP inhibitor (PARPi) and angiogenic inhibitor has been shown to be effective as a first-line or second-line maintenance regimen to synergistically exert antitumor effects, which prompts u...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huiwen, Chen, Xue, Tang, Chenpeng, Luo, Xiangjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647199/
https://www.ncbi.nlm.nih.gov/pubmed/38021157
http://dx.doi.org/10.7150/jca.89082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647199/
https://www.ncbi.nlm.nih.gov/pubmed/38021157
http://dx.doi.org/10.7150/jca.89082

Ejemplares similares